Immunofluorescent staining of the BC marker KRT5 demonstrated no significant difference (all p > 0.1) in positive cells between control, WT and activated KRAS over-expressing cells (58.0% lenti control vs 65.5% WT KRAS vs 61.4% in activated KRAS-expressing cultures; Fig. 5a). This evidence concerns the gene KRAS and breast cancer.